Pure Global

Conditioned Open Label Placebo for Postoperative Pain Management - Trial NCT06107595

Access comprehensive clinical trial information for NCT06107595 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre de Médecine Intégrative et Complémentaire (CEMIC) and is currently Not yet recruiting. The study focuses on Pain, Postoperative. Target enrollment is 222 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06107595
Not yet recruiting
behavioral
Trial Details
ClinicalTrials.gov • NCT06107595
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Conditioned Open Label Placebo for Postoperative Pain Management
A Randomized Controlled Trial Evaluating the Efficacy of Conditioned Open Label Placebo (COLP) to Limit Opioid Reliance for Postoperative Pain Management

Study Focus

Pain, Postoperative

Placebo

Interventional

behavioral

Sponsor & Location

Centre de Médecine Intégrative et Complémentaire (CEMIC)

Lausanne, Switzerland

Timeline & Enrollment

N/A

Nov 06, 2023

Dec 01, 2025

222 participants

Primary Outcome

Opioids consumption

Summary

The primary objective is to evaluate the efficacy of two Conditioned Open Label Placebos
 (COLP): COLP pill and COLP odor to reduce opioid intake for postoperative (thoracic and
 spinal surgery) pain management compared to the opioid only usual treatment (TAU).

ICD-10 Classifications

During surgical operation
During surgical operation
During surgical operation
Pain, unspecified
Postoperative intestinal obstruction

Data Source

ClinicalTrials.gov

NCT06107595

Non-Device Trial